Advertisement

Topics

Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 Pipeline Review, H1 2017 [Updated: 30052017] Prices from USD $3500

11:36 EDT 31 May 2017 | BioPortfolio Report Blog

Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 Pipeline Review, H1 2017

Summary

According to the recently published report 'SerineThreonine Protein Kinase Pim 3 Pipeline Review, H1 2017'; Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 Serine/threonineprotein kinase Pim3 is an enzyme encoded by the PIM3. It prevents apoptosis. It contribute to tumorigenesis through the delivery of survival signaling through phosphorylation of BAD which induces release of the antiapoptotic protein BclXL, by regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity.

The report 'SerineThreonine Protein Kinase Pim 3 Pipeline Review, H1 2017' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Immunology and Infectious Disease which include indications Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Chronic Lymphocytic Leukemia CLL, Pancreatic Cancer, Bladder Cancer, Hematological Tumor, Influenza virus A Infections, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, NonSmall Cell Lung Carcinoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Transitional Cell Carcinoma Urothelial Cell Carcinoma and Viral Infections.

Scope

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1
The report reviews Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1targeted therapeutics and enlists all their major and minor projects
The report assesses Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 Pipeline Review, H1 2017 [Updated: 30052017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Serine/Threonine Protein Kinase Pim 3 Pim 3 Oncogene or PIM3 or EC 2.7.11.1 Pipeline Review, H1 2017 [Updated: 30052017] Prices from USD $3500"

Quick Search
Advertisement
 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...